These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20097953)

  • 1. The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase.
    Otocka-Kmiecik A; Orłowska-Majdak M
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():668-77. PubMed ID: 20097953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase, a cardioprotective enzyme: continuing issues.
    Getz GS; Reardon CA
    Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paraoxonase 1, 2 and 3 in humans.
    Rajkovic MG; Rumora L; Barisic K
    Biochem Med (Zagreb); 2011; 21(2):122-30. PubMed ID: 22135851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
    Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
    Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.
    Soran H; Schofield JD; Liu Y; Durrington PN
    Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: The role of paraoxonase in cardiovascular diseases.
    Kowalska K; Socha E; Milnerowicz H
    Ann Clin Lab Sci; 2015; 45(2):226-33. PubMed ID: 25887882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase and atherosclerosis-related cardiovascular diseases.
    Chistiakov DA; Melnichenko AA; Orekhov AN; Bobryshev YV
    Biochimie; 2017 Jan; 132():19-27. PubMed ID: 27771368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The growing importance of PON1 in cardiovascular health: a review.
    Macharia M; Hassan MS; Blackhurst D; Erasmus RT; Matsha TE
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):443-53. PubMed ID: 22673025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.
    Kim DS; Marsillach J; Furlong CE; Jarvik GP
    Pharmacogenomics; 2013 Sep; 14(12):1495-515. PubMed ID: 24024900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonases-1, -2 and -3: What are their functions?
    Furlong CE; Marsillach J; Jarvik GP; Costa LG
    Chem Biol Interact; 2016 Nov; 259(Pt B):51-62. PubMed ID: 27238723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
    Deakin SP; James RW
    Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paraoxonase gene family and atherosclerosis.
    Ng CJ; Shih DM; Hama SY; Villa N; Navab M; Reddy ST
    Free Radic Biol Med; 2005 Jan; 38(2):153-63. PubMed ID: 15607899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of paraoxonases: a brief review.
    Draganov DI; La Du BN
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):78-88. PubMed ID: 14579013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of paraoxonase (PON1) activity.
    Costa LG; Vitalone A; Cole TB; Furlong CE
    Biochem Pharmacol; 2005 Feb; 69(4):541-50. PubMed ID: 15670573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.
    She ZG; Chen HZ; Yan Y; Li H; Liu DP
    Antioxid Redox Signal; 2012 Mar; 16(6):597-632. PubMed ID: 21867409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates.
    Marsillach J; Richter RJ; Costa LG; Furlong CE
    Curr Protoc; 2021 Jan; 1(1):e25. PubMed ID: 33484495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
    Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
    Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant paraoxonase 1 activity in the metabolic syndrome.
    Sentí M; Tomás M; Fitó M; Weinbrenner T; Covas MI; Sala J; Masiá R; Marrugat J
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5422-6. PubMed ID: 14602783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients.
    Parra S; Marsillach J; Aragonés G; Beltrán R; Montero M; Coll B; Mackness B; Mackness M; Alonso-Villaverde C; Joven J; Camps J
    J Infect Dis; 2010 Feb; 201(4):627-34. PubMed ID: 20078196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.